No Data
No Data
6 ASX All Ords Shares Lifted to 'Strong Buy' Consensus Ratings for the New Year
Integral Diagnostics Ltd. Sees Shift in Substantial Holdings
Integral Diagnostics' Merger Could Deliver Revenue Synergies -- Market Talk
Integral Diagnostics Target Price Raised 21% to A$3.50/Share by Macquarie>IDX.AU
Internal Diagnostics' Set for Upside to Returns Post Merger With Capitol Health, Jarden Says
Jarden Sticks to Its Buy Rating for Integral Diagnostics Ltd. (IDX)